AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was ...
Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 trials for VRDN-003 in TED are underway, with a BLA submission planned by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback